Shilpa Medicare Ltd
SHILPAMED
Company Profile
Business description
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company's product range includes over 44 oncology and non-oncology APIs. It uses nano and micro technology in its drug identification and formulation. The operating segments of the company are Pharmaceutical products and services, which is the key revenue-generating segment; and Power sales. Geographically, the group derives revenue from India and Outside India, of which prime revenue is generated from India.
Contact
Hyderabad Road
Number 12-6-214/A-1
Shilpa House
RaichurKA584135
INDT: +91 8532238704
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
931
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,570.90 | 30.80 | -0.36% |
| CAC 40 | 8,154.51 | 31.93 | 0.39% |
| DAX 40 | 22,287.56 | 27.09 | -0.12% |
| Dow JONES (US) | 43,725.89 | 450.76 | -1.02% |
| FTSE 100 | 8,659.37 | 3.60 | -0.04% |
| HKSE | 23,477.92 | 900.94 | 3.99% |
| NASDAQ | 19,764.02 | 198.34 | -0.99% |
| Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
| NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
| S&P 500 | 6,071.32 | 46.20 | -0.76% |
| S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
| SSE Composite Index | 3,379.11 | 28.33 | 0.85% |